Can a common cholesterol drug shrink skin lumps in kids with rare liver disease?
NCT ID NCT05488067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of atorvastatin (Lipitor) in 15 children with Alagille syndrome who had skin cholesterol deposits called xanthomas. The children took the drug for 6 months, and doctors graded the size and number of the lumps. The goal was to see if the drug could reduce these deposits without causing serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atorvastatin (Lipitor)
- What this could lead to
- If it works, this could offer a way to shrink or prevent disfiguring skin cholesterol lumps in children with Alagille syndrome.
- What could go wrong
- This is a very small, single-center study with only 15 children. The results may not apply to all patients, and statins can cause muscle pain or liver issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, 201102, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug shows promise for babies with rare liver disorders
- Personalized combo therapy aims to overcome drug resistance in kidney cancer
- New study tracks Real-World safety of odevixibat in rare liver disease
- Statins take on COPD: could a heart drug curb lung Flare-Ups?
- New drug livmarli tracked for Long-Term safety in kids with rare liver disorders
- Liver drug maralixibat tested for Long-Term safety in rare disease patients